AU666586B2 - Cyclopeptides - Google Patents

Cyclopeptides

Info

Publication number
AU666586B2
AU666586B2 AU50399/93A AU5039993A AU666586B2 AU 666586 B2 AU666586 B2 AU 666586B2 AU 50399/93 A AU50399/93 A AU 50399/93A AU 5039993 A AU5039993 A AU 5039993A AU 666586 B2 AU666586 B2 AU 666586B2
Authority
AU
Australia
Prior art keywords
asp
arg
ala
gly
denotes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU50399/93A
Other versions
AU5039993A (en
Inventor
Beate Diefenbach
Brunhilde Felding-Habermann
Roland Haubner
Gunter Holzemann
Alfred Jonczyk
Horst Kessler
Guido Melzer
Friedrich Ripmann
Jochen Wermuth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU5039993A publication Critical patent/AU5039993A/en
Application granted granted Critical
Publication of AU666586B2 publication Critical patent/AU666586B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention relates to novel cyclopeptides of the formula I Cyclo-(A-B-C-D-Arg) I in which A and B in each case independently of one another denote Ala, Asn, Asp, Arg, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val, C denotes Asp or Asp(O-C1-4-alkyl) and D denotes Gly or Ala, at least two of the amino acid radicals indicated being present in the D-form, and their salts. These compounds act as integrin inhibitors and can be used in particular for the prophylaxis and treatment of circulation disorders and in tumour therapy.
AU50399/93A 1992-11-06 1993-11-01 Cyclopeptides Expired AU666586B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4237456 1992-11-06
DE4237456A DE4237456A1 (en) 1992-11-06 1992-11-06 cyclopeptides

Publications (2)

Publication Number Publication Date
AU5039993A AU5039993A (en) 1994-05-19
AU666586B2 true AU666586B2 (en) 1996-02-15

Family

ID=6472232

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50399/93A Expired AU666586B2 (en) 1992-11-06 1993-11-01 Cyclopeptides

Country Status (21)

Country Link
EP (1) EP0596350B1 (en)
JP (1) JP3681764B2 (en)
KR (1) KR100238894B1 (en)
CN (1) CN1038751C (en)
AT (1) ATE154037T1 (en)
AU (1) AU666586B2 (en)
CA (1) CA2102447C (en)
CZ (1) CZ286170B6 (en)
DE (2) DE4237456A1 (en)
DK (1) DK0596350T3 (en)
ES (1) ES2105041T3 (en)
GR (1) GR3024550T3 (en)
HU (1) HU215600B (en)
MX (1) MX9306885A (en)
NO (1) NO309864B1 (en)
PL (1) PL177772B1 (en)
RU (1) RU2129563C1 (en)
SK (1) SK280597B6 (en)
TW (1) TW340849B (en)
UA (1) UA43822C2 (en)
ZA (1) ZA938281B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111372586B (en) * 2017-11-20 2023-07-25 诺麦塔制药有限公司 Composition for preventing, improving or treating bone loss diseases comprising CHP

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816449A (en) * 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816449A (en) * 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents

Also Published As

Publication number Publication date
DK0596350T3 (en) 1997-12-29
PL177772B1 (en) 2000-01-31
NO934003L (en) 1994-05-09
AU5039993A (en) 1994-05-19
NO934003D0 (en) 1993-11-05
DE59306654D1 (en) 1997-07-10
UA43822C2 (en) 2002-01-15
CN1093090A (en) 1994-10-05
NO309864B1 (en) 2001-04-09
EP0596350B1 (en) 1997-06-04
ZA938281B (en) 1994-06-07
DE4237456A1 (en) 1994-05-11
RU2129563C1 (en) 1999-04-27
PL300935A1 (en) 1994-05-16
HUT68321A (en) 1995-06-28
EP0596350A1 (en) 1994-05-11
CN1038751C (en) 1998-06-17
CA2102447C (en) 2007-04-10
JP3681764B2 (en) 2005-08-10
CA2102447A1 (en) 1994-05-07
TW340849B (en) 1998-09-21
KR940011479A (en) 1994-06-21
MX9306885A (en) 1995-01-31
JPH0892282A (en) 1996-04-09
ES2105041T3 (en) 1997-10-16
SK280597B6 (en) 2000-04-10
SK121793A3 (en) 1995-06-07
ATE154037T1 (en) 1997-06-15
KR100238894B1 (en) 2000-01-15
CZ286170B6 (en) 2000-02-16
HU215600B (en) 1999-01-28
GR3024550T3 (en) 1997-12-31
CZ235293A3 (en) 1994-07-13

Similar Documents

Publication Publication Date Title
CA2120303A1 (en) Cyclic adhesion inhibitors
NZ248377A (en) Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors
PT804252E (en) METALLIC CHELTER AGENTS THAT CONTAINS DIAMOND MONOAMINES AND THIOIS
ES2144179T3 (en) CYCLIC ADHESION INHIBITORS.
UA42747C2 (en) Peptide derivatives, pharmaceutical composition and method for stimulating growth hormone releasing
MX9703621A (en) Novel amino acid derivatives with improved multi-drug resistance activity.
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
MX9703643A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein.
UA41355C2 (en) Agent for treating neuro-aids
ZA943744B (en) Therapeutic substituted guanidines
CA2148194A1 (en) Cyclopeptides of the formula i
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
IL104314A0 (en) Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
ES2160643T3 (en) COMPOSITIONS CONTAINING G-CSF AND PROTEIN OF UNION TO TNF.
GB8826428D0 (en) Antithrombin
NO941151L (en) Linear adhesion inhibitors
AU666586B2 (en) Cyclopeptides
CA2096933A1 (en) Compounds and compositions which inhibit bone resorption
DE3569541D1 (en) Pharmacologically active peptides
HUP0003357A2 (en) Cyclic azapeptides with angiogenic effect, pharmaceutical compositions comprising them, processes for producing thereof and their use
CA2290739A1 (en) New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy
EP0613375A4 (en) Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof.
EP0248231A3 (en) Pharmacologically active peptides
GR3015132T3 (en) Novel ureas and thioureas, preparation thereof and application in therapy.
NZ268039A (en) Use of efaroxan in treating parkinson's disease